LAG3 and acute myeloid leukemia: Figure 6C illustrated that those individuals with low PD-1 expression levels and low SRGS scores had a longer OS than those with low PD-1 expression levels and high SRGS scores. In individuals with strong PD-1 expression levels, a lower risk score indicated a survival rate that was significantly improved. In the TCGA-AML cohort, similar survival trends were identified across the four AML patient groups stratified by the SRGS scores and CTLA4 (Figure 6F) or LAG3 (Figure 6I) expression.